OTTAWA (dpa-AFX) - Takeda Canada, a subsidiary of Takeda Pharmaceutical Co.
Ltd. (TAK), Thursday announced that it has finalized a Letter of Intent with
pan-Canadian Pharmaceutical Alliance or pCPA for Livtencity, which is used to
treat patients suffering from post-transplant cytomegalovirus infection.

The biotechnology company added that the beta herpes virus infection commonly
affects transplant patients and sometimes lead to loss of transplanted organ or
even death.

Following the agreement, the procedures regarding individual listing of
Livtencity will be initiated, depending on the respective province or territory.

Currently, Takeda's stock is moving down 0.62 percent, to $13.31 on the New York
Stock Exchange.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX